This combination is designed to support appetite awareness, cravings management, and balanced energy as part of a provider-guided plan. Metformin ER (extended-release) supports glucose balance and metabolic health, while low-dose naltrexone (LDN) may help regulate appetite and cravings when prescribed off-label.

No. Metformin is FDA-approved for type 2 diabetes but not for weight loss. LDN is not FDA-approved for weight loss or obesity treatment. Both may be prescribed off-label by a licensed provider based on clinical judgment and individual health goals.

• Metformin ER: Reduces sugar production in the liver, improves how the body uses insulin, and helps stabilize energy levels. Some studies suggest it may indirectly support appetite regulation in certain individuals.
  
• LDN: Works on endorphin and opioid receptor pathways, which may influence appetite regulation, cravings, and inflammation.
  

Together, these may complement one another under provider supervision to support sustainable lifestyle changes.

Some members report:

• More stable energy from meals
  
• Greater awareness of appetite cues
  
• Reduced cravings or emotional eating triggers
  
• Improved sense of balance when transitioning off dieting or other therapies
  

Results vary and depend on health status, adherence, and provider guidance.

• Metformin ER: The most common side effects are digestive issues such as nausea, diarrhea, or stomach upset. Long-term use may lower vitamin B12 levels.
• LDN: May cause vivid dreams, nausea, or mild headaches in some individuals. These effects are typically dose-dependent and may improve with adjustment.

Metformin can lower vitamin B12 over time, which is why providers often recommend monitoring or supplementing. LDN may interfere with opioid-based medications and is not suitable for people using opioid pain treatments. Always share your full medication and supplement list with your provider before starting.

Neither Metformin nor LDN are FDA-approved for weight loss. Some studies suggest Metformin may support modest weight reduction in certain populations when used off-label. LDN’s role in weight management is still under study and not clinically established. Any benefits depend on individual health factors, adherence, and provider supervision.

This combination may not be suitable for individuals who are:

• Pregnant or breastfeeding
  
• Living with severe kidney or liver disease
  
• Experiencing recurrent vitamin B12 deficiency
  
• Currently using opioid medications or with opioid dependence
  
• Managing uncontrolled heart disease or hypertension
  

Your provider will carefully review your history before prescribing.